Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Head and neck cancer
Phase 1 Pilot: HB-200 HPV16 E6/E7 mRNA vaccine for HPV+ head and neck cancer.
This study evaluates alternate dosing of HB-201/HB-202 as a post-treatment intervention in HPV16+ head and neck squamous cell carcinoma patients with a positive NavDx test but no radiographic evidence of disease.…
NCT06373380 - New trial
Head and neck cancer
Phase II Trial of Reduced-Dose Radiotherapy in HPV+ Oropharyngeal Cancer
This trial led by Georgetown University evaluates if omitting chemotherapy from full-dose radiotherapy (66Gy) maintains cancer control while reducing long-term side effects in Stage I–II HPV/p16+ oropharyngeal…
NCT06902623 - New trial
Head and neck cancer
Phase 2 Cetuximab EGFR-directed mAb in de-escalated radiation therapy for HPV+ carcinoma
Researchers at Memorial Sloan Kettering Cancer Center are evaluating reduced radiation doses with standard chemotherapy post-induction in advanced HPV-positive oropharyngeal carcinoma. Eligible patients must…
NCT06984861 - New trial
Head and neck cancer
Phase II Trial: Erlotinib EGFR Inhibitor in Triple Oral Regimen
This Phase II study sponsored by Mayo Clinic evaluates the safety, feasibility, and potential efficacy of a triple oral chemotherapy regimen (methotrexate, erlotinib, celecoxib) in rural Midwest patients with…
NCT06997068 - New trial
Brain and CNS tumors
Phase 2 Trial of Ruxolitinib JAK1 Inhibitor in Combination Therapy for Glioblastoma
This randomized Phase 2 trial evaluates the safety and effectiveness of adding ruxolitinib to standard radiation and temozolomide in patients with newly diagnosed glioblastoma. The study features two treatment arms…
NCT06991101 - New trial
Brain and CNS tumors
Phase I 8R-70CAR T cells: IL-8 receptor modified CD70-targeted immunotherapy
A Phase I trial evaluating safety and feasibility of ex-vivo expanded autologous IL-8 receptor-modified CD70 CAR T cell therapy in patients with CD70+ adult glioblastoma and pediatric high-grade gliomas. Sponsored by…
NCT05353530 - New trial
Neuroendocrine and adrenal tumors
Phase I trial of rhIL-15 immune agonist in relapsed/refractory neuroblastoma.
This study evaluates escalating IV doses of rhIL-15 combined with dinutuximab, irinotecan, and temozolomide administered in 21-day cycles. It enrolls children and young adults (ages 3–35) with relapsed or refractory…
NCT06995872 - New trial
Melanoma
Phase 1 Study of GME751, PD-L1/PD-L2 Inhibitor in Melanoma Adjuvant Setting
This randomized, double-blind study compares the pharmacokinetics, efficacy, safety, and immunogenicity of GME751 versus US-/EU-licensed pembrolizumab administered intravenously as adjuvant therapy in patients with…
NCT06153238 - New trial
Prostate cancer
Phase 2 CT-SBRT, image-guided precision radiotherapy for localized prostate cancer.
This trial evaluates CT-guided SBRT with intrafraction motion monitoring delivered over five fractions in patients with localized prostate cancer. The study assesses treatment efficacy and side effects while…
NCT06995053 - New trial
Ovarian cancer
Phase II Mirvetuximab Soravtansine ADC, FOLR1-directed tubulin inhibitor
This single-arm Phase II trial at University of Alabama at Birmingham evaluates neoadjuvant carboplatin plus mirvetuximab in advanced-stage serous ovarian cancer with high FRα expression. The study documents…
NCT04606914 - New trial
Kidney cancer
Phase I/II Trial of Bicalutamide, an Androgen Receptor Inhibitor in Renal Cancer
This open-label study evaluates the safety and efficacy of bicalutamide plus sunitinib administered in cycles among advanced renal cell carcinoma patients with progression after prior receptor tyrosine kinase…
NCT06222593 - New trial
Liver and bile duct cancer
Phase 1 RPCAR01 CAR T Cells Targeting GPC3 in Advanced Hepatocellular Carcinoma
This phase 1 trial evaluates RPCAR01 CAR T cell monotherapy combined with lymphodepleting chemotherapy in patients with advanced or metastatic GPC3-positive hepatocellular carcinoma. The first-in-human study uses…
NCT06968195 - New trial
Other cancers
Phase II Ivonescimab: PD-1/VEGF-targeted bispecific antibody in thymic carcinoma.
This trial examines ivonescimab monotherapy in previously treated thymic carcinoma patients with IV infusions every three weeks. Patients undergo CT scans and biospecimen collection to assess treatment effects.…
NCT06980077 - New trial
Sarcoma and GIST
Phase II Study of Pomalidomide, Thalidomide Derivative Vascular Inhibitor in Kaposi Sarcoma
This trial evaluates pomalidomide monotherapy for Kaposi Sarcoma patients. Eligible participants receive pomalidomide orally in cycles, with treatment continuation based on response. Conducted at multiple US centers…
NCT04577755 - New trial
Sarcoma and GIST
Phase I trial: Zanzalintinib cMet/VEGFR inhibitor with checkpoint inhibitors.
This dose-finding study evaluates zanzalintinib combined with ipilimumab and nivolumab for metastatic soft tissue sarcoma in patients with progression on 2nd–4th line therapy. Conducted at Washington University…
NCT06968988 - New trial
Uterine (endometrial) cancer
Phase III T-DXd, a HER2-directed ADC with topoisomerase I inhibition in advanced endometrial cancer
This randomized controlled trial evaluates first-line treatment in advanced or recurrent HER2-expressing endometrial cancer. Patients receive T-DXd with rilvegostomig or pembrolizumab versus standard chemotherapy…
NCT06989112 - New trial
Lymphoma
Phase II Obinutuzumab CD20-targeted mAb Trial in Relapsed or Refractory Follicular Lymphoma
This randomized Phase II trial by the National Cancer Institute compares obinutuzumab used alone or combined with umbralisib, lenalidomide, or standard chemotherapy to treat patients with grade I–IIIa relapsed or…
NCT03269669 - New trial
Lymphoma
Phase 1 BAFFR-CAR T Cells: BAFF-R-directed immunotherapy for relapsed B-cell NHL
This study evaluates BAFFR-targeted CAR T cells in patients with relapsed or refractory B-cell non-Hodgkin's lymphomas—including diffuse large B-cell, follicular, marginal zone, and mantle cell subtypes—using…
NCT05370430 - New trial
Chronic lymphocytic leukemia
Phase II pirtobrutinib BTK inhibitor trial in relapsed CLL/SLL.
M.D. Anderson Cancer Center is conducting this Phase II trial evaluating a time-limited, four‐week combination of pirtobrutinib, venetoclax, and obinutuzumab in relapsed chronic lymphocytic leukemia/small lymphocytic…
NCT06967610 - New trial
Chronic lymphocytic leukemia
Phase 3 Study of BGB-16673, a BTK protein degrader, in CLL/SLL patients.
This study compares BGB-16673 monotherapy against investigator's choice regimens (idelalisib plus rituximab, bendamustine plus rituximab, or venetoclax plus rituximab retreatment) in patients with chronic lymphocytic…
NCT06846671 - New trial
Acute myeloid leukemia and MDS
Phase 1b/2 APVO436 bispecific anti-CD123/CD3 antibody study
This open-label, dose-finding trial evaluates APVO436 with venetoclax and azacitidine in adult patients with newly diagnosed CD123+ AML ineligible for induction therapy. Conducted across multiple U.S. centers and…
NCT06634394 - New trial
Acute lymphoblastic leukemia
Phase 3 trial: Imatinib mesylate, a Bcr-Abl/c-KIT/PDGF inhibitor, in Ph+ ALL.
Children’s Oncology Group is evaluating imatinib mesylate with varied chemotherapy regimens—with or without stem cell transplant—to treat newly diagnosed Philadelphia chromosome–positive and ABL-class fusion positive…
NCT03007147 - New trial
Other blood cancers and transplant
Phase I/II trial of AZD5492, trispecific T cell-engaging antibody targeting CD20.
This open-label study employs dose escalation and expansion to evaluate safety, pharmacokinetics, pharmacodynamics, and efficacy of AZD5492 monotherapy in patients with relapsed or refractory CD20+ B-cell…
NCT06542250 - New trial
Other blood cancers and transplant
Phase 1 trial of LYT-200, a galectin-9 directed mAb.
This open-label, multi-center study evaluates LYT-200 administered via IV infusion as monotherapy or combined with venetoclax and hypomethylating agents in patients with relapsed/refractory AML or high-risk MDS in a…
NCT05829226 - New trial
Other blood cancers and transplant
Phase 2 ASTX727 Trial: Cytidine Deaminase Inhibition in Accelerated/Blast-Phase MPNs
This Phase 2 trial by the National Cancer Institute compares ASTX727 alone versus ASTX727 plus iadademstat, an LSD1 inhibitor, in patients with accelerated or blast-phase Philadelphia chromosome-negative…
NCT06661915 - Trial result
Other cancers
Precision Strikes: KRAS-G12D, RET & TRK Therapies Post Record ORRs and ctDNA Proves the Earliest Truth-Teller
Targeted drugs stole the show: KRAS-G12D inhibitors shrank pancreatic tumors in >50% of patients, RET and NTRK blockers logged 40-70% response rates across rare fusions, and HER2-selective TKIs hit 70% in mutant lung…
- New trial
Other cancers
Frontier Pipeline: DLL3 Trispecifics, PSMA Radioligands, B7-H3 ADCs—and a First Look at EPR-Imaging PET
Among 25 fresh studies, several stand out: - XB628 (NKG2A / PD-L1 bispecific) opens the door for NK-cell activation in advanced solid tumors. - Ifinatamab deruxtecan vs docetaxel could make B7-H3 ADCs the next line…
- Trial result
Breast cancer
Pembro Lead-In Lifts ORR to 47% and Extends OS to 26 mo in Metastatic TNBC
In a single-institution Phase II trial (NCT02752685) enrolling 50 patients with metastatic triple-negative breast cancer (TNBC), regardless of PD-L1 status, investigators compared two sequential “run-in” strategies…
NCT02752685 - Trial result
Breast cancer
Oncolytic HSV TVEC + Taxane/AC Regimen Yields 46% pCR and 87% 5-Year DFS in Stage II-III TNBC
Talimogene laherparepvec (TVEC) is an intratumoral herpes oncolytic virus engineered to secrete GM-CSF and enhance antitumor immunity. In a single-arm Phase 1/2 study (NCT02779855) involving 46 patients with stage…
NCT02779855 - Trial result
Breast cancer
Ultrasound TVR > 50% at Week 6 Pinpoints 94% of pCRs on Keynote-522 in Early TNBC
In the prospective ARTEMIS study (NCT02276443), 150 patients with stage I–III triple-negative breast cancer received the KN-522 regimen, which includes paclitaxel (a taxane), carboplatin (a platinum-based…
NCT02276443
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.